Caris Life Sciences (CAI) said Monday it has launched an artificial intelligence tool designed to help doctors predict whether patients with high-grade serous ovarian cancer, or HGSOC, will become resistant to platinum-based chemotherapy.

The tool is part of the company's Caris AI Insights platform. It identifies molecular patterns linked to platinum resistance and generates a risk score and a prediction of whether the cancer is likely to be platinum-sensitive or platinum-resistant, the company said.

The tool is available through the Caris Molecular Tumor Board Report when ordering the Caris' tissue-based cancer test, MI Cancer Seek, the company added.

Shares of Caris Life Sciences rose nearly 3.5% in the session.

Price: 18.79, Change: +0.64, Percent Change: +3.53